Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Policy / Regulatory

NMPA Releases 2025 Priority Approval Directory for Eight High-End Medical Device Categories

Fineline Cube Dec 29, 2025
Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Fineline Cube Dec 29, 2025
Company Drug

BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL

Fineline Cube Dec 29, 2025
Company Deals

Danatlas Raises RMB 150M to Advance Synthetic Lethality Drug Pipeline

Fineline Cube Mar 3, 2025

Beijing-headquartered Danatlas, a first-in-class drug developer in the synthetic lethality field, has reportedly raised RMB...

Company Deals

Magnet Biomedicine and Eli Lilly Partner on Molecular Glue Therapeutics

Fineline Cube Mar 3, 2025

US-based molecular glue specialist Magnet Biomedicine has entered into a collaboration and license agreement with...

Company Drug

AstraZeneca and Amgen’s Tezspire Shows Positive Results in Phase III Study

Fineline Cube Mar 3, 2025

AstraZeneca (NASDAQ: AZN) and Amgen (NASDAQ: AMGN) have jointly announced positive results from the Phase...

Company Deals Digital

Baidu Health Partners with Jolly Pharma to Boost Digital Drug Marketing

Fineline Cube Mar 3, 2025

Baidu Health, an internet giant, has entered into a partnership with Zhejiang Jolly Pharmaceutical Co.,...

Company Deals

Duality Biotherapeutics Updates IPO Filing with HKSE under Chapter 18A Rules

Fineline Cube Mar 3, 2025

China-based Duality Biotherapeutics, Inc. updated its initial public offering (IPO) filing to the Hong Kong...

Company Drug

CARsgen’s CT041 Awarded Breakthrough Therapy Designation for Gastric Cancer

Fineline Cube Mar 3, 2025

CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that its chimeric antigen receptor (CAR) T-cell therapy,...

Company Deals

Huge Dental Files for Hong Kong IPO with Diverse Dental Product Portfolio

Fineline Cube Mar 3, 2025

Shandong-based dental materials company Huge Dental Limited has made an initial public offering (IPO) filing...

Drug

CSPC Pharmaceutical’s Sirolimus Receives BTD for Malignant PEComa Treatment

Fineline Cube Mar 3, 2025

China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received Breakthrough Therapy Designation...

Company Deals

Pulnovo Medical Raises USD 100M in Series C Financing for Global Expansion

Fineline Cube Mar 3, 2025

Wuxi-based Pulnovo Medical Limited, a developer of medical devices for pulmonary hypertension and heart failure,...

Company Deals

Grand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs

Fineline Cube Mar 3, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the sale of 4,947,181 shares in...

Company

AI in Healthcare: Accelerating Applications in Diagnostics and Multi-omics Analysis

Fineline Cube Mar 2, 2025

The breakthrough technology of DeepSeek has significantly accelerated the application of AI in the medical...

Company

Biointron Biologics Files for Public Offering, Aims for BSE Listing

Fineline Cube Mar 2, 2025

On February 11, Biointron Biologics released its tutoring filing report for the public offering of...

Company

Biocytogen Completes DeepSeek Localization, Integrates with “Thousand Mice, Ten Thousand Antibodies” Plan

Fineline Cube Mar 1, 2025

On February 28, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that it has completed...

Company

BeiGene’s Q4 and 2024 Financials Highlight Significant Growth and Product Success

Fineline Cube Feb 28, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) released financial results and corporate updates from...

Company

Zai Lab Q2 and Full-Year 2024 Report Shows Sales Growth and Loss Reduction

Fineline Cube Feb 28, 2025

China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q2 and full-year 2024...

Company

Viatris Q4 and Full-Year Results Show Greater China Growth

Fineline Cube Feb 28, 2025

US generics giant Viatris (NASDAQ: VTRS) released its Q4 and full-year 2024 financial results. In...

Company Deals

SciClone Pharmaceuticals Licenses Eisai’s Tasurgratinib for China

Fineline Cube Feb 28, 2025

China-based SciClone Pharmaceuticals Inc. announced a licensing agreement with Eisai Co., Ltd (TYO: 4523), securing...

Company Drug

Fosun Pharmaceutical’s XS-03 Gets NMPA Green Light for CRC Study

Fineline Cube Feb 28, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has...

Company Deals

Sino Biopharmaceutical and Sciwind Biosciences Partner on CPX102 Development

Fineline Cube Feb 28, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced a strategic partnership with compatriot firm Sciwind Biosciences...

Company Drug

Bayer’s BlueRock Therapeutics Gets Fast Track for OpCT-001 Therapy

Fineline Cube Feb 28, 2025

German pharmaceutical giant Bayer (ETR: BAYN) and its wholly owned subsidiary BlueRock Therapeutics LP announced...

Posts pagination

1 … 140 141 142 … 602

Recent updates

  • Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio
  • Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal
  • Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing
  • Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China
  • BDgene Doses First Patient with BD920 CRISPR Gene Therapy for HPV-16 HSIL
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Company Drug

Boan Biotech Ships First Batch of Boyoujing Aflibercept Biosimilar in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.